ImmuPharma agrees study design with Avion for lupus programme Lupuzor
(Alliance News) - ImmuPharma PLC on Monday confirmed together with partner Avion Pharmaceuticals that an adaptive phase 2/3 trial will be the best design for the next clinical study of Lupuzor in patients with -systemic lupus…